CDK6 and Miyoshi myopathy: DHCE treatment downregulated the cyclin D1, CDK4, and CDK6 protein levels, leading to excessive activation of the G1 checkpoint, which confirmed that DHCE could cause G0/G1 phase CCA in BTZ-R MM cells.